Table 3

Primary and secondary outcomes for sexual and intravenous drug behaviour change interventions

StudyOutcomeOR or SMD
(95% CI)
Primary outcomes
Iguchi95Acquisition of HIVOR 0.37 (0.11 to 1.28)
Secondary outcomes
Avants96Number of weeks had sex without a condomSMD −0.326 (−0.594 to −0.059)
Cottler97No sex if no condomOR 0.99 (0.70 to 1.40)
Cottler97Used a condom in the last 30 daysOR 1.01 (0.74 to 1.36)
Cottler97‘Improved’ condom useOR 1.31 (0.98 to 1.77)
Eldridge98Log mean proportion of vaginal sex protectedSMD 0.925 (0.356 to 1.494)
Kotranski99100% condom use or abstinence (vaginal or unspecified)OR 1.50 (1.02 to 2.22)
Cottler97100% condom use (vaginal or unspecified)OR 0.95 (0.66 to 1.37)
Margolin100100% condom use (vaginal or unspecified)OR 3.94 (0.94 to 16.58)
Hershberger101100% condom use (vaginal or unspecified)OR 2.43 (1.37 to 4.32)
Hershberger101Proportion of sex protected (vaginal or unspecified)SMD 0.08 (−0.07 to 0.22)
Iguchi95Improvement in condom use (dichotomous)OR 1.03 (0.76 to 1.40)
Sorensen102 (maintenance group)Proportion of sex protected (vaginal or unspecified)SMD 0.661 (−0.397 to 1.718)
Sorensen102 (detoxification group)Proportion of sex protected (vaginal or unspecified)SMD 0.031 (−0.737 to 0.800)